Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trialYuan Li, Hai‐Qiang Mai|Nature Communications|2023Cited by 45
Data from Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal CarcinomaRui You, Ming‐Yuan Chen, De‐Chen Lin et al.|Unknown|2023Cited by 0